Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Neo-adjuvant and Adjuvant Therapy for Poor-prognosis BCLC A HCC
NCT05113186Phase 2Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2022; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05113186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113186.